MedPath

Role of Ormeloxifene in abnormal uterine bleeding

Phase 3
Completed
Conditions
Health Condition 1: - Health Condition 2: N800- Endometriosis of uterus
Registration Number
CTRI/2018/12/016561
Lead Sponsor
GMCH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
59
Inclusion Criteria

ALL WOMEN IN REPRODUCTIVE AND PERIMENOPAUSAL AGE GROUP PRESENTING WITH AUB

Exclusion Criteria

women with bulky uterus presenting with pressure symptoms.

submucosal fibroid

endometrial hyperplasia and polyp, complex adnexal mass, acute aub requiring immediate surgical intervention, coagulopathy, systemic disease, history of breast malignancy.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
PABC score to assess menstrual blood lossTimepoint: end of 3rd and 6th month
Secondary Outcome Measures
NameTimeMethod
effect of dysmenorrhoes, menstrual periodicity, side effects, hemoglobinTimepoint: end of 3rd and 6th month
© Copyright 2025. All Rights Reserved by MedPath